Variants of GCKR affect both β-cell and kidney function in patients with newly diagnosed type 2 diabetes: The verona newly diagnosed type 2 diabetes study 2

Diabetes Care

Volumn 34, Issue 5, 2011, Pages 1205-1210

  Bonetti, Sara ^a   Trombetta, Maddalena ^a   Boselli, Maria Linda ^a   Turrini, Fabiola ^a   Malerba, Giovanni ^a   Trabetti, Elisabetta ^a   Pignatti, Pier Franco ^a   Bonora, Enzo ^a   Bonadonna, Riccardo C ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOKINASE REGULATORY PROTEIN; GLUCOSE; INSULIN; REGULATOR PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; INSULIN-SECRETING CELLS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 79956161644     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-2218     Document Type: Article

References (25)

1. de la Iglesia N, Mukhtar M, Seoane J, Guinovart JJ, Agius L. The role of the regulatory protein of glucokinase in the glucose sensory mechanism of the hepatocyte. J Biol Chem 2000;275:10597-10603 (Pubitemid 30202126)
2. Vaxillaire M, Cavalcanti-Proença C, Dechaume A, et al.; DESIR Study Group. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes 2008;57:2253-2257
3. Saxena R, Voight BF, Lyssenko V, et al.; Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-1336
4. Sparsø T, Andersen G, Nielsen T, et al. The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 2008;51:70-75 (Pubitemid 50003447)
5. Onuma H, Tabara Y, Kawamoto R, et al. The GCKR rs780094 polymorphism is associated with susceptibility of type 2 diabetes, reduced fasting plasma glucose levels, increased triglycerides levels and lower HOMA-IR in Japanese population. J Hum Genet 2010;55:600-604
6. Ridker PM, Pare G, Parker A, et al. Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet 2008;82:1185-1192
7. Tang W, Basu S, Kong X, et al. Genomewide association study identifies novel loci for plasma levels of protein C: the ARIC study. Blood 2010;116:5032-5036
8. Gunnarsdóttir KA, Jensen MB, Zahrieh D, et al. CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. Breast Cancer Res Treat 2010;123:163-169
9. Qi Q, Wu Y, Li H, et al. Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population. Diabetologia 2009;52:834-843
10. Bi M, Kao WH, Boerwinkle E, et al. Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC Study. PLoS ONE 2010;5:e11690
11. Köttgen A, Pattaro C, Böger CA, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 2010;42:376-384
12. Bonadonna RC, Heise T, Arbet-Engels C, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010;95:5028-5036
13. Bonetti S, Trombetta M, Malerba G, et al. Variants and haplotypes of TCF7L2 are associated with {beta}-cell function in patients with newly diagnosed type 2 diabetes: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 1. J Clin Endocrinol Metab 2011;96:E389-E393
14. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254 (Pubitemid 46768608)
15. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000;151:190-198 (Pubitemid 30463650)
16. Cobelli C, Toffolo GM, Dalla Man C, et al. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007;293:E1-E15 (Pubitemid 47105910)
17. Mari A, Camastra S, Toschi E, et al. A model for glucose control of insulin secretion during 24 h of free living. Diabetes 2001;50(Suppl. 1):S164-S168 (Pubitemid 32148245)
18. Davidovich O, Kimmel G, Shamir R. GEVALT: an integrated software tool for genotype analysis. BMC Bioinformatics 2007;8:36
19. Lin CH, Yeakley JM, McDaniel TK, Shen R. Medium- to high-throughput SNP genotyping using VeraCode microbeads. Methods Mol Biol 2009;496:129-142
20. Cali' AM, Bonadonna RC, Trombetta M, Weiss R, Caprio S. Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. J Clin Endocrinol Metab 2008;93:1767-1773 (Pubitemid 351656516)
21. Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R. Betacell function across the spectrum of glucose tolerance in obese youth. Diabetes 2005;54:1735-1743 (Pubitemid 40774888)
22. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-3277 (Pubitemid 37430080)
23. Thomas MC, Macisaac RJ, Jerums G, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (National Evaluation of the Frequency of Renal Impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 2009;32:1497-1502
24. Ninomiya T, Perkovic V, de Galan BE, et al.; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-1821
25. Bonora E, Targher G, Formentini G, et al. Themetabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004;21:52-58